- Home
- VLO vs ZTS Comparison
VLO vs ZTS Comparison
Compare VLO & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VLO | ZTS |
|---|---|---|
| Founded | 1980 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.9B | 54.8B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | VLO | ZTS |
|---|---|---|
| Price | $199.51 | $128.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 11 |
| Target Price | ★ $184.24 | $166.60 |
| AVG Volume (30 Days) | 3.2M | ★ 4.6M |
| Earning Date | 01-29-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.38% | 1.67% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | ★ 7.57 | 5.94 |
| Revenue | ★ $122,687,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | N/A | $3.04 |
| Revenue Next Year | $4.28 | $4.99 |
| P/E Ratio | $26.60 | ★ $21.44 |
| Revenue Growth | N/A | ★ 2.68 |
| 52 Week Low | $99.00 | $115.25 |
| 52 Week High | $204.14 | $177.00 |
Technical Indicators
Market Signals| Indicator | VLO | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 60.71 |
| Support Level | $190.11 | $126.34 |
| Resistance Level | $204.14 | $129.95 |
| Average True Range (ATR) | 6.38 | 2.79 |
| MACD | 1.33 | 0.51 |
| Stochastic Oscillator | 81.33 | 89.89 |
Price Performance
Historical ComparisonAbout VLO Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 15 refineries, with a total throughput capacity of 3.2 million barrels a day in the US, Canada, and the United Kingdom. Valero also owns 12 ethanol plants with capacity of 1.6 billion gallons a year and holds a 50% stake in Diamond Green Diesel, which can produce 1.2 billion gallons per year of renewable diesel.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.